Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Understanding and predicting brain penetration for CNS-targeted drugs

There are numerous strategies available incorporating in silico, in vitro and in vivo tools for optimising brain exposure for CNS-target drugs.

What do you think are the pros and cons of each strategy? At the Romark Medicinal Chemistry Symposium that was held recently in Liverpool, our Director of DMPK, Tim Schulz-Utermoehl, provided an overview of this area.

Check out the slides following the link below:

Romark Medicinal Chemistry Syposium 2018 Slideset

Why don’t you let us know your thoughts!

Latest News

View All

Three of UK’s top drug discovery CROs…

Sygnature Discovery expands DMPK capabilities with acquisition…

Sygnature strengthens DMPK team

Senior appointments enhance Sygnature Discovery’s DMPK capabilities

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

Areas of interest

Discovery Discipline
Therapeutic Areas
The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.